-The trial is being conducted at the University of Alabama at Birmingham (UAB) under noted psychedelic researcher Dr. Peter Hendricks- -This exploratory study is the first investigation of
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics
Thermo Fisher has agreed to pay $3.1 billion to acquire Sweden’s Olink Holding to expand its capabilities in the proteomics market, the two companies announced
Listen to the article 5 min This audio is auto-generated. Please let us know if you have feedback. By the numbers Q3 sales: $21.35 billion
Dive Brief: Fear and doubt created by the emergence of new obesity and diabetes drugs may affect medtech stocks for years, according to analysts at
Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: GE HealthCare has cut the
What variables, if any, can predict the intensity of a psychedelic mystical experience? Perhaps a better question to ask is: why would identifying these
The company has said that its novel drug SEFA-6179 was well tolerated in Phase I trials. Credit: Shutterstock / Studio Romantic Dutch biotech firm, NorthSea
The gene therapy will target patients with biallelic mutations in the RPE65 gene. Credit: Dr_Microbe via Getty Images. Spanish biotech SpliceBio has signed a licensing
The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City